AGENDA
Utah Department of Health 	 
Pharmacy and Therapeutics Committee 	
Thursday, September 20, 2018 
7:15 a.m. to 8:45 a.m. 
Cannon Health Building
Room 125 

Persons who wish to address the P&T Committee may contact Bryan S. Larson at (bslarson@utah.gov) prior to the meeting, or sign up to provide comments at the meeting. Public comments will be limited to 3 minutes per speaker or organization due to time constraints. 
 
1)  Call to order - McKay Robinson, PharmD, Chair
a)  Announce Quorum 
 
2)  Welcome and Introductions - McKay Robinson, PharmD, Chair
a)  Review and Approval of Minutes 
b)  Housekeeping 
                   
3)  DUR Board Update - Robyn Seely, PharmD 
 
4)  Review 
a)  Hemophilia Factor IX - Elena Martinez
i)  Alphanine, Alprolix, Bebulin, Benefix, Feiba, Idelvion, Ixinity, Mononine, Profilnine, Rebinyn, Rixubis	
b)  Combination Factor VIII/VWF - Valerie Martinez, PharmD 
i)	Alphanate, Humate-P, Wilate, Vonvendi
c)  Public Comment 
i)  CSL Behring - Katheleen Pinto, PharmD
ii)	Bioverativ - Alex Bitting, PharmD
iii)  Shire - Kevin Kassabian, MBA, PharmD
iv)  Novo Nordisk - Margaret Fisher, PharmD 
d)  Other States Report - Bryan S. Larson, PharmD            
e)  Committee Discussion/Questions  
f)  Committee Action 
 
5)   Next Meeting October 18, 2018 Topic: Anticoagulants (LMWH, Factor Xa Inhibitors) 

6)  Adjourned - McKay Robinson, PharmD, Chair

Individuals with questions about accessibility or requesting special accommodations for this meeting should contact Bryan S. Larson at bslarson@utah.gov or (801) 538-6149 
 
The foundation documents used for most reviews are prepared by the University of Utah, College of Pharmacy, and are posted on the P&T Committee website after the meeting. Manufacturers wishing to submit any additional materials they would like reviewed as part of the process to: 
 
Dr. Joanne LaFleur 
College of Pharmacy 
30 South 2000 East 
SLC, UT 84112-5820

All materials must be clearly labeled that they are submitted for consideration as part of the state of Utah Medicaid Preferred Drug List Program review process. Materials must be received at least 60 days before the scheduled review date. Materials most useful to support the evidence-based process include any new evidence (information from clinical trials or studies when possible), unpublished materials the company would like considered as part of the process, or any other materials not likely to be included in a literature search. 
 
Tentative Upcoming Pharmacy & Therapeutics Committee Schedule
        
Month
18 Oct 2018
Topic
Anticoagulants (LMWH, Factor Xa Inhibitors)
Agents
Apixaban, Betrixaban, Dabigatran, Dalteparin, Desirudin, Edoxaban, Enoxaparin,
Fondaparinux, Rivaroxaban

Month
15 Nov 2018
Topic
Migraine Prophylaxis
Agents
Divalproex, Eptinezumab, Erenumab, Galcanezumab, Fremanezumab, Propranolol, Timolol, Topiramate    

Month
20 Dec 2018
Topic
No meeting
Agents
No meeting

Month
17 Jan 2019
Topic
No meeting
Agents
No meeting

Month
21 Feb 2019
Topic
No meeting
Agents
No meeting

Month
21 Mar 2019
Topic
Insulins - Rapid Acting
Insulins - Basal
ACE Inhibitors/ACE Inhibitor Combinations
Agents
Benazepril, Benazepril/HCTZ, Captopril, Captopril/HCTZ, Enalapril, Enalapril/HCTZ, Fosinopril, Fosinopril/HCTZ, Lisinopril, Lisinopril/HCTZ, Moexipril, Moexipril/HCTZ, Perindopril, Quinapril /HCTZ, Ramipril,  Trandolapril 

Please note: all topics are tentative and subject to change.